
The Health Insurance Review and Assessment Service assessed that there is a high likelihood that the obesity drug "Mounjaro" (generic name: tirzepatide) will be recognized as meeting the criteria for insurance coverage. The service also predicted that institutional mechanisms are now in place to enable price comparison and disclosure of non-covered drugs, making it possible to disclose prices for non-covered pharmaceuticals such as obesity treatments in the future.
At a press briefing held by the Health Insurance Review and Assessment Service on the 19th, the eligibility of Mounjaro for insurance coverage was a key issue. Eli Lilly had applied for coverage in June for indications including adult type 2 diabetes (diseases targeted for treatment).
Lee So-young, permanent vice president of insurance pricing at HIRAS, stated, "A prior evaluation recognizing the appropriateness of Mounjaro for coverage was issued. Subsequently, price negotiations with the National Health Insurance Service broke down, but an application for coverage has been resubmitted after additional indications were added." She continued, "The period from application to notifying the pharmaceutical company of the coverage decision is set at 150 days. The process is proceeding without any particular issues, and there will be nothing particularly different from HIRAS's perspective." This remark implies that since Mounjaro has already been recognized as appropriate for coverage in the past, it is expected to receive similar recognition this time as well.
It was projected that once Mounjaro's coverage is finalized, its price will be adjusted to a reasonable level. Lee said, "From the public's perspective, obesity drugs are non-covered medications, so there is significant price variation and they are very expensive." She added, "If one of the multiple indications becomes covered, the drug price for the remaining non-covered indications will also converge toward a certain reasonable level because a covered price exists."
Price disclosure and comparison for non-covered drugs, including obesity treatments, are also expected to become possible. Lee stated, "We currently disclose non-covered medical service items, and we have established regulatory grounds to allow the disclosure of prices for non-covered pharmaceuticals as well." She added, "For items that are social issues, we will disclose non-covered prices to enable rational choices."

Hong Seung-gwon, director of the Health Insurance Review and Assessment Service, stated, "Establishing a management system for non-covered Jeonju items is a direction we must move forward in." He added, "We have formed a Task Force (TF) with the National Health Insurance Service and the Ministry of Health and Welfare to improve the non-covered management system. We will keep this in mind and examine it closely."
Additionally, Director Hong emphasized innovation through the use of AI (artificial intelligence). He stated, "We will drive innovation in review and evaluation using artificial intelligence and data with greater momentum." He revealed, "What I definitely want to accomplish during my term is establishing a review system that ensures medical care is clear and fair through AI." He added, "Beyond post-hoc reviews, we will develop a value-based review and evaluation system that prevents unnecessary medical utilization and prioritizes the quality of healthcare and patient health outcomes."
The plan includes using AI to create medical records, enabling medical institutions to claim medical benefits from HIRAS more quickly, and automatically detecting excessive medical care to improve operational efficiency. To this end, 16 GPUs (graphics processing units) were secured from NVIDIA last month.
Director Hong also stated, "We will strive to strengthen regional, essential, and public healthcare." He added, "We will establish an institutional foundation to ensure that essential medical services such as emergency care, childbirth, and pediatric care are provided stably, and that the efforts and expertise of medical professionals are fairly compensated."